Piper腹地醫療資本

2023年6月3日

無限的生物,臨床分期和下一代精密腫瘤學公司發展創新療法針對染色體外的DNA (ecDNA)患者癌基因放大癌症——宣布關閉1億C係列融資共同飛躍拜耳,拜耳公司投資部門的影響,和RA資本管理參與額外的新投資者,部門資產管理和Piper腹地醫療資金。無限的生物將使用融資推進bbi - 355,第一個ecDNA-directed療法(ecDTx),通過有意義的臨床讀數從正在進行的1/2期臨床試驗患者oncogene-amplified癌症。靶向治療和免疫療法在治療傳統很大程度上是無效的。oncogene-amplified癌症患者。和無限的生物是第一家完全致力於開發新的療法oncogene-amplified癌症患者,特別是那些由ecDNA啟用。缺席在正常健康組織,ecDNA觀察到早期癌症的14%和40%的轉移性癌症和驅動腫瘤形成和抵抗目前的治療方法。無限的生物是利用漏洞的一個獨特的理解ecDNA生物學治療的潛在變化,目的是提供400000患者在美國每年新診斷之前棘手的致癌基因放大癌症。一輪融資提出了將基金的初始臨床開發bbi - 355,作為一個代理,結合選擇治療方法,對多個癌症跡象與癌基因擴增被評估的1/2加強期臨床試驗(NCT05827614)。bbi - 355是一種口頭,有力,和選擇性CHK1抑製劑已被證明功能型綜合致命到ecDNA-bearing oncogene-amplified癌細胞。和新的一輪融資也將支持無限進步的生物分化的臨床前管道ecDTx候選人和其專有ecDNA診斷臨床試驗測定,回聲(ecDNA窩藏致癌基因),正在開發與索菲亞遺傳學。C係列融資包括從現有投資者參與忠誠管理和研究公司LLC拱Venture Partners, Nextech投資,威靈頓管理、頂點企業HC, Redmile集團測量員資本(Citadel公司),GT醫療Capital Partners,亞曆山大風險投資,PFM健康科學,標誌資本,城山企業。 And in connecting with the funding, Fabio Pucci, Ph.D., Senior Director of Venture Investments Health at Leaps by Bayer, will join the Boundless Bio Board of Directors. KEY QUOTES: “At Leaps by Bayer, we invest in fundamental breakthroughs in healthcare. The ability to address oncogene-amplified cancers has remained one of the industry’s greatest challenges in the treatment of cancer. We are thrilled to support Boundless Bio, a company whose innovations have the potential to impact the lives of patients who currently have no effective standard of care.” — Juergen Eckhardt, M.D., EVP and Head of Leaps by Bayer “We are excited to have Leaps by Bayer join our world-class investor syndicate and to welcome Fabio Pucci to our Board of Directors. The support from new investors along with the continued commitment of our existing investors emphasizes our momentum and progress in bringing the first ecDNA-directed therapies to patients with oncogene-amplified cancers.” — Zachary Hornby, President and Chief Executive Officer of Boundless Bio Trending on Pulse 2.0